Enliven Therapeutics Inc
Veridion Score
Composite trend over time
Why is ELVN moving today?
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ELVN.
ELVN insider activity
Enliven Therapeutics Inc
2 insiders bought in the last 90 days
Net selling: -$53.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC | Insider | sell | $45.00 | 46,776 | 6,555,102 | $2.1M | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC | Insider | sell | $45.38 | 787,024 | 6,601,878 | $35.7M | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC | Insider | sell | $45.00 | 1,477 | 219,405 | $66K | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC | Insider | sell | $45.38 | 24,846 | 220,882 | $1.1M | SEC Form 4 |
| 2026-06-22 | 2026-06-17 | Hohl Benjamin | Insider | sell | $44.75 | 1,238 | 51,000 | $55K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 92 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moELVN contract awards, year to date.
Public federal awards linked to this ticker.
ELVN lobbying filings, year to date.
Registered lobbying filings matched to Enliven Therapeutics Inc.